Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Behcet's disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Behcet's disease. Displaying page 1 of 1.
    EudraCT Number: 2014-005390-36 Sponsor Protocol Number: UoL001109 Start Date*: 2016-02-17
    Sponsor Name:The University of Liverpool
    Full Title: Optimal utilisation of biologic drugs in Behçet’s Disease: a randomised controlled trial of infliximab (IFX) verses alpha interferon (aIFN), with genotyping and metabolomic profiling, towards a str...
    Medical condition: Behcets Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10004212 Behcet's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2022-003024-41 Sponsor Protocol Number: 20190531 Start Date*: 2023-01-25
    Sponsor Name:Amgen Inc
    Full Title: A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet’s Disease or 5 Years of Age or Older With Juv...
    Medical condition: Subjects with active Behçet's Disease or Juvenile Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10004212 Behcet's disease LLT
    20.0 100000004859 10079454 Systemic juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Not Authorised) IT (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002264-41 Sponsor Protocol Number: P160932J Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude randomisée multicentrique évaluant l’efficacité et la tolérance de l’infliximab comparativement au Cyclophosphamide dans les formes sévères de maladie de Behçet " Multicenter, randomized, pro...
    Medical condition: Induction Therapy with Anti-TNF vs Cyclophosphamide in severe Behçet disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000017240 10004212 Behcet's disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000845-39 Sponsor Protocol Number: FARM12LTAT Start Date*: 2017-05-12
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: THE ROLE OF ANTI TNF ALPHA AGENTS IN BEH¿ET¿S DISEASE REFRACTORY TO STANDARD OF CARE THERAPIES: MULTICENTER RANDOMIZED CONTROLLED PROSPECTIVE PARALLEL GROUP SINGLE-BLIND TRIAL TO EVALUATE THE 6 MON...
    Medical condition: BEH¿ET¿S DISEASE REFRACTORY TO STANDARD OF CARE THERAPIES
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10004215 Behcets disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024152-29 Sponsor Protocol Number: Start Date*: 2011-09-02
    Sponsor Name:University Hospital of Tübingen
    Full Title: Canakinumab for Behçet`s Disease Resistant to Standard Treatment (CanBeDisT)
    Medical condition: Behçet`s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021428 - Immune system disorders 10004213 Behcet's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002190-37 Sponsor Protocol Number: P140302 Start Date*: 2015-10-30
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in patients with Behçet disease : STELABEC
    Medical condition: Behçet disease STELABEC-1: patients with oral ulcers STELABEC-2 : patients with active posterior uveitis or panuveitis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10004212 Behcet's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002787-27 Sponsor Protocol Number: 20190530 Start Date*: 2021-03-15
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From ...
    Medical condition: Subjects with active Behçet’s Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10004212 Behcet's disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Ongoing) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002108-25 Sponsor Protocol Number: CC-10004-BCT-002 Start Date*: 2015-06-17
    Sponsor Name:Amgen Inc.
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY, FOLLOWED BY AN ACTIVE-TREATMENT PHASE TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE...
    Medical condition: SUBJECTS WITH ACTIVE BEHÇET’S DISEASE
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10004212 Behcet's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-013901-33 Sponsor Protocol Number: CAIN457C2303E1 Start Date*: 2009-11-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior...
    Medical condition: Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011237-27 Sponsor Protocol Number: CAIN457C2303 Start Date*: 2009-10-15
    Sponsor Name:Novartis Pharma Services Ag
    Full Title: A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated ...
    Medical condition: Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) FR (Completed) DE (Completed) AT (Prematurely Ended) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001316-26 Sponsor Protocol Number: APHP200007 Start Date*: 2022-09-12
    Sponsor Name:Assistance Publique Hôpitaux de Paris / DRCI
    Full Title: Multicenter, randomized, prospective trial comparing the Efficacy and Safety of Adalimumab to that of Tocilizumab in severe uveitis of Behçet’s disease UVB Study
    Medical condition: severe uveitis of Behçet’s disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10071139 Behcet's uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001125-27 Sponsor Protocol Number: CL3-78989-002 Start Date*: 2013-01-15
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitis EYEGUARD TM -B
    Medical condition: Behçet’s disease uveitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004866 10071139 Behcet's uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) GR (Prematurely Ended) PT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-004876-10 Sponsor Protocol Number: ASF-EVER.1 Start Date*: 2007-08-06
    Sponsor Name:Department of Ophthalmology at St. Franziskus Hospital
    Full Title: single center study on safety and efficacy of everolimus in patients with endogenous intermediate and posterior uveitis
    Medical condition: Uveitis, specially endogenous interemdiate and posterior uveitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001243-67 Sponsor Protocol Number: CAIN457A2208 Start Date*: 2011-07-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label proof-of-concept study with a double-masked, dose-ranging component to assess the effects of AIN457 in patients with noninfectious uveitis
    Medical condition: Intermediate, posterior or pan-uveitis of noninfectious origin
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    14.0 10015919 - Eye disorders 10036370 Posterior uveitis LLT
    14.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001610-42 Sponsor Protocol Number: X052130/CL3-78989-005 Start Date*: 2013-01-24
    Sponsor Name:XOMA (US) LLC
    Full Title: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
    Medical condition: Non-infectious Intermediate, Posterior, or Pan- Uveitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    17.0 10038359 - Renal and urinary disorders 10069034 Tubulointerstitial nephritis and uveitis syndrome PT
    17.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    17.0 100000004862 10036370 Posterior uveitis LLT
    17.0 10015919 - Eye disorders 10066681 Acute uveitis LLT
    17.0 100000004866 10071139 Behcet's uveitis LLT
    17.0 10015919 - Eye disorders 10042745 Sympathetic uveitis LLT
    17.0 10015919 - Eye disorders 10012692 Diabetic uveitis PT
    17.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Completed) GB (Prematurely Ended) ES (Completed) GR (Prematurely Ended) AT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004973-29 Sponsor Protocol Number: CL3-78989-019 Start Date*: 2014-08-13
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A safety open-label study of Gevokizumab in the treatment of patients with chronic non-infectious Uveitis disease, an eXtension study. The EYEGUARD-X study.
    Medical condition: chronic non-infectious uveitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10022557 Intermediate uveitis LLT
    18.0 10038359 - Renal and urinary disorders 10069034 Tubulointerstitial nephritis and uveitis syndrome PT
    18.0 100000004862 10036370 Posterior uveitis LLT
    18.0 100000004866 10071139 Behcet's uveitis LLT
    18.0 10015919 - Eye disorders 10042745 Sympathetic uveitis LLT
    18.0 10015919 - Eye disorders 10012692 Diabetic uveitis PT
    18.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Completed) PT (Completed) ES (Completed) AT (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001609-25 Sponsor Protocol Number: X052131/CL3-78989-006 Start Date*: 2013-01-02
    Sponsor Name:XOMA (US) LLC
    Full Title: A RandomizEd, Double-masked, Placebo-controlled Study of the SafetY and Efficacy of GevokizUmAb in the TReatment of Subjects with Non-infectious IntermeDiate, Posterior, or Pan- uveitis Currently C...
    Medical condition: Non-infectious Intermediate, Posterior, or Pan- Uveitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    17.0 10038359 - Renal and urinary disorders 10069034 Tubulointerstitial nephritis and uveitis syndrome PT
    17.0 100000004862 10036370 Posterior uveitis LLT
    17.0 100000004866 10071139 Behcet's uveitis LLT
    17.0 10015919 - Eye disorders 10042745 Sympathetic uveitis LLT
    17.0 10015919 - Eye disorders 10012692 Diabetic uveitis PT
    17.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) PT (Completed) IT (Completed) GR (Prematurely Ended) ES (Completed) PL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 06:59:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA